{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=11", "query": { "intervention": "One cycle", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2770, "total_pages": 277, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T09:27:32.228Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02418195", "title": "miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "ketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 247, "start_date": "2015-04-20", "completion_date": "2020-12-30", "has_results": true, "last_update_posted_date": "2022-08-30", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418195" }, { "nct_id": "NCT00068770", "title": "Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2003-10", "completion_date": "2006-05", "has_results": true, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 7, "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068770" }, { "nct_id": "NCT00186888", "title": "Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinoblastoma", "Retinal Neoplasm" ], "interventions": [ { "name": "Enucleation", "type": "PROCEDURE" }, { "name": "Vincristine, Carboplatin", "type": "DRUG" }, { "name": "Focal Therapies", "type": "PROCEDURE" }, { "name": "External Beam Radiation", "type": "RADIATION" }, { "name": "Vincristine and Topotecan", "type": "DRUG" }, { "name": "Vincristine + Carboplatin + Etoposide", "type": "DRUG" }, { "name": "vincristine, cyclophosphamide, and doxorubicin", "type": "DRUG" }, { "name": "Vincristine, Carboplatin and Etoposide", "type": "DRUG" }, { "name": "Periocular carboplatin", "type": "PROCEDURE" }, { "name": "G-CSF", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 107, "start_date": "2005-04-07", "completion_date": "2024-11-12", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186888" }, { "nct_id": "NCT03387553", "title": "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Breast Cancer Female", "Breast Cancer, Male", "Invasive Breast Cancer", "HER2-positive Breast Cancer", "HER2 Positive Breast Carcinoma", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Dendritic Cell Vaccine (DC1)", "type": "BIOLOGICAL" }, { "name": "Neoadjuvant Chemotherapy", "type": "DRUG" }, { "name": "Curative Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-06-06", "completion_date": "2026-02-19", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387553" }, { "nct_id": "NCT01629329", "title": "Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Headaches" ], "interventions": [ { "name": "Aspirin, Acetaminophen, Caffeine pills", "type": "DRUG" }, { "name": "Prochlorperazine 10mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albert Einstein Healthcare Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 93, "start_date": "2010-11", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629329" }, { "nct_id": "NCT06306131", "title": "Phase II Study of Ovulation in Obese Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pregnancy Prevention" ], "interventions": [ { "name": "Levonorgestrel 1.5 milligram", "type": "DRUG" }, { "name": "Meloxicam 15 milligram", "type": "DRUG" }, { "name": "calcium carbonate 750 milligram", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "InnovaGyn, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 4, "start_date": "2023-12-10", "completion_date": "2025-11-30", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06306131" }, { "nct_id": "NCT00303108", "title": "Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2005-12", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2016-11-03", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Port Richey", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303108" }, { "nct_id": "NCT01878617", "title": "A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Craniospinal Irradiation with boost to the primary tumor site", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Aerobic Training", "type": "OTHER" }, { "name": "Neurocognitive Remediation", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 660, "start_date": "2013-06-23", "completion_date": "2031-10-13", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 14, "location_summary": "Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01878617" }, { "nct_id": "NCT02501096", "title": "A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 357, "start_date": "2015-07-22", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 50, "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Oro Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02501096" }, { "nct_id": "NCT00704379", "title": "Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 94, "start_date": "2008-06", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-24T09:27:32.228Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00704379" } ] }